{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:51Z","timestamp":1786985091671,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.beem.2023.101817","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T12:09:39Z","timestamp":1692878979000},"page":"101817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk"],"prefix":"10.1016","volume":"37","author":[{"given":"Cesar Luiz","family":"Boguszewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2023.101817_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.709936","article-title":"Human growth and growth hormone: from antiquity to the recombinant age to the future","volume":"12","author":"Graber","year":"2021","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2023.101817_bib2","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/EJE-18-0306","article-title":"Therapy of endocrine disease: growth hormone replacement therapy in adults: 30 years of personal clinical experience","volume":"179","author":"J\u00f8rgensen","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2023.101817_bib3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/er.2018-00166","article-title":"Growth hormone's links to cancer","volume":"40","author":"Boguszewski","year":"2019","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.beem.2023.101817_bib4","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0400","article-title":"The science behind the relations among cancer, height, growth patterns, and growth hormone axis","volume":"30","author":"Boguszewski","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.beem.2023.101817_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s11102-021-01173-0","article-title":"Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors: a review of research and clinical practice","volume":"24","author":"Boguszewski","year":"2021","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.beem.2023.101817_bib6","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-15-0873","article-title":"GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults","volume":"174","author":"Allen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2023.101817_bib7","article-title":"Usefulness and potential pitfalls of long-acting growth hormone analogs","volume":"12","author":"Yuen","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2023.101817_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2023.101788","article-title":"Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: challenging issues, benefits, and risks","author":"H\u00f6ybye","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2023.101817_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-17-1073","article-title":"Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial","volume":"178","author":"Johannsson","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2023.101817_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1056\/NEJM196201112660207","article-title":"Growth hormone. 2. Clinical use of human growth hormone","volume":"266","author":"Raben","year":"1962","journal-title":"N Engl J Med"},{"issue":"8649","key":"10.1016\/j.beem.2023.101817_bib11","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(89)92328-3","article-title":"Beneficial effects of growth hormone treatment in GH-deficient adults","volume":"1","author":"J\u00f8rgensen","year":"1989","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.beem.2023.101817_bib12","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM198912283212605","article-title":"The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency","volume":"321","author":"Salomon","year":"1989","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beem.2023.101817_bib13","doi-asserted-by":"crossref","first-page":"C5","DOI":"10.1530\/EJE-20-1455","article-title":"Adult growth hormone deficiency guidelines: more difficult than it seems to incorporate into clinical practice universally","volume":"184","author":"Yuen","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2023.101817_bib14","doi-asserted-by":"crossref","first-page":"D1","DOI":"10.1530\/EJE-21-0534","article-title":"Should patients with adult GH deficiency receive GH replacement?","volume":"186","author":"J\u00f8rgensen","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2023.101817_bib15","article-title":"ESE audit on management of adult growth hormone deficiency in clinical practice","author":"Martel-Duguech","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2023.101817_bib16","doi-asserted-by":"crossref","first-page":"P35","DOI":"10.1530\/EJE-21-1186","article-title":"Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement","volume":"186","author":"Boguszewski","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.beem.2023.101817_bib17","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1210\/clinem\/dgac199","article-title":"Long-term safety of growth hormone in adults with growth hormone deficiency: overview of 15809 GH-treated patients","volume":"107","author":"Johannsson","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2023.101817_bib18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-14-1123","article-title":"Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study","volume":"172","author":"Child","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2023.101817_bib19","doi-asserted-by":"crossref","first-page":"bvad054","DOI":"10.1210\/jendso\/bvad054","article-title":"Long-term effectiveness and safety of GH replacement therapy in adults \u2265 60 years: data from NordiNet\u00ae IOS and ANSWER","volume":"7","author":"Biller","year":"2023","journal-title":"J Endocr Soc"},{"issue":"Suppl A","key":"10.1016\/j.beem.2023.101817_bib20","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ghir.2004.03.013","article-title":"KIMS Study Group; KIMS International Board. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults","volume":"14","author":"Feldt-Rasmussen","year":"2004","journal-title":"Growth Horm IGF Res"},{"issue":"11","key":"10.1016\/j.beem.2023.101817_bib21","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2023.101817_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"Sherlock","year":"2010","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.beem.2023.101817_bib23","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1210\/jc.2014-3787","article-title":"Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies","volume":"100","author":"Pappachan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2023.101817_bib24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/cen.12848","article-title":"Growth hormone replacement does not increase mortality in patients with childhood-onset growth hormone deficiency","volume":"83","author":"Berglund","year":"2015","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2023.101817_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/EJE-16-0450","article-title":"Life expectancy in patients with pituitary adenoma receiving growth hormone replacement","volume":"176","author":"Olsson","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2023.101817_bib26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/cen.13502","article-title":"Long-term safety of growth hormone: a combined registry analysis","volume":"88","author":"Stochholm","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"8","key":"10.1016\/j.beem.2023.101817_bib27","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S2213-8587(20)30163-7","article-title":"Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study","volume":"8","author":"S\u00e4vendahl","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2023.101817_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.980979","article-title":"What do we do now that the long-acting growth hormone is here","volume":"13","author":"Miller","year":"2022","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2023.101817_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4158\/EP.14.2.143","article-title":"Compliance and persistence in pediatric and adult patients receiving growth hormone therapy","volume":"14","author":"Rosenfeld","year":"2008","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.beem.2023.101817_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17446651.2019.1689119","article-title":"Adult growth hormone deficiency: clinical advances and approaches to improve adherence","volume":"14","author":"Yuen","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2023.101817_bib31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/joim.13382","article-title":"Growth hormone deficiency in adults with hypopituitarism - what are the risks and can they be eliminated by therapy?","volume":"290","author":"Johannsson","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.beem.2023.101817_bib32","doi-asserted-by":"crossref","first-page":"1040046","DOI":"10.3389\/fendo.2022.1040046","article-title":"Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation","volume":"13","author":"Bidlingmaier","year":"2022","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2023.101817_bib33","doi-asserted-by":"crossref","first-page":"e1358","DOI":"10.1210\/clinem\/dgaa049","article-title":"Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial","volume":"105","author":"Johannsson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2023.101817_bib34","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/cen.14273","article-title":"Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone","volume":"93","author":"Otsuka","year":"2020","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2023.101817_bib35","doi-asserted-by":"crossref","first-page":"568","DOI":"10.20945\/2359-3997000000186","article-title":"Growth hormone in the tumor microenvironment","volume":"63","author":"Chesnokova","year":"2019","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2023.101817_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrendo.2010.171","article-title":"Growth hormone, the insulin-like growth factor axis, insulin and cancer risk","volume":"7","author":"Clayton","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2023.101817_bib37","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1002\/ijc.28589","article-title":"Insulin-like growth factor I and risk of breast cancer by age and hormone receptor status - a prospective study within the EPIC cohort","volume":"134","author":"Kaaks","year":"2014","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.beem.2023.101817_bib38","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1158\/1055-9965.EPI-12-0481-T","article-title":"Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition","volume":"21","author":"Price","year":"2012","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"6","key":"10.1016\/j.beem.2023.101817_bib39","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1055-9965.EPI-13-1210-T","article-title":"Insulin-like growth factor-I and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition","volume":"23","author":"Schmidt","year":"2014","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"10","key":"10.1016\/j.beem.2023.101817_bib40","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1158\/1055-9965.EPI-11-0179","article-title":"Concentrations of IGF-I and IGFBP-3 and brain tumor risk in the European Prospective Investigation into Cancer and Nutrition","volume":"20","author":"Rohrmann","year":"2011","journal-title":"Cancer Epidemiol, Biomark Prev"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X2300091X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X2300091X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:59:21Z","timestamp":1761497961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X2300091X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1521690X2300091X"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2023.101817","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2023.101817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101817"}}